The Biden administration is stepping up oversight of nursing home patients with a schizophrenia diagnosis to help reduce the inappropriate use of antipsychotic medications in the facilities.
Beginning this month, the Centers for Medicare & Medicaid Services will conduct targeted, off-site audits to see if nursing homes are properly assessing and coding residents diagnosed as schizophrenic. Erroneous diagnoses increase the risk of poor care and of inappropriate use of antipsychotic medications, the agency said.
Antipsychotics are dangerous among the frail nursing home population because of their potential side effects, including death. The effort is the latest action under the ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.